Senores Pharma to acquire two products of USFDA approved ANDAs from Teva Pharma USA
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-08-13 05:45 GMT | Update On 2025-08-13 05:45 GMT
Advertisement
Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has signed agreement to acquire two products of USFDA approved Abbreviated New Drug Applications (“ANDAs”) from Teva Pharmaceuticals USA, Inc.
The addressable opportunity of the acquired ANDAs in the USA is ~USD 38 Mn (MAT December 2024)* as per IQVIA and ~USD 120 Mn (MAT June 2025)# as per the specialty data aggregator Symphony.
The acquisition will be funded through the Initial Public Offer (“IPO”) proceeds raised by SPL. This is in line with the Objects of the IPO stated in theRed Herring Prospectus.
Senores Pharmaceuticals Limited is a global, researchdriven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The companies’ current portfolio includes 70 ANDA and 27 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing ofcomplex genericscertified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 308 product registrations and 719 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“API”).
Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.